Inge M. Svane - Publications

Immune-cytokine signature predicts survival in patients with advanced melanoma treated with oncolytic adenovirus TILT-123 and chemotherapy and IL-2-free adoptive TIL therapy.

Journal: Journal for immunotherapy of cancer

Published: July 27, 2026

Randomized phase II trial of nivolumab and ipilimumab with or without stereotactic body radiation therapy in patients with metastatic castration-resistant prostate cancer: the CheckPRO, CA209-8TY trial.

Journal: Journal for immunotherapy of cancer

Published: June 29, 2026

Immune checkpoint inhibitor therapy after tumor-infiltrating lymphocytes in unresectable melanoma.

Journal: Journal for immunotherapy of cancer

Published: June 10, 2026

Corrigendum to "Discontinuation of BRAF/MEK inhibitor therapy after long-lasting response: Clinical outcomes in advanced melanoma" [Eur J Cancer 234 (2026) 116200].

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 21, 2026

Sentinel node biopsy and survival in cutaneous melanoma: a nationwide population-based cohort study.

Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Published: May 21, 2026

Fresh-blood immune profiling of immune-related adverse events in real-world patients identifies organ-specific and steroid responsiveness signatures.

Journal: Immuno-oncology technology

Published: April 20, 2026

Progression risk among responders to PD-1/PD-L1 blockade is primarily stratified by response depth: A nationwide cohort study of 2127 patients with melanoma, RCC, and NSCLC.

Journal: European journal of cancer (Oxford, England : 1990)

Published: March 22, 2026

Five-year survival impact of adjuvant anti-PD-1 therapy in a nationwide cohort of stage III melanoma.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: March 19, 2026

Quantifying the efficacy-effectiveness gap in first line treatment of metastatic melanoma.

Journal: Journal of the National Cancer Institute

Published: March 09, 2026

Receptor-defined targeting of a genomically unique melanoma-enriched noncanonical antigen.

Journal: Signal transduction and targeted therapy

Published: February 20, 2026

Real-World Outcomes of Nivolumab and Ipilimumab in Metastatic Melanoma as Third Line and Beyond.

Journal: International journal of cancer

Published: January 28, 2026

Safety and feasibility of blood-derived multiple antigen-specific endogenously derived T cells (MASE-T) for metastatic melanoma.

Journal: Immuno-oncology technology

Published: January 23, 2026